Skip to main content
  • Dabigatran reversal agent receives full FDA approval

    The U.S. Food and Drug Administration has granted full approval for idarucizumab (Praxbind), a reversal agent for the anticoagulant dabigatran etexilate mesylate (Pradaxa), Boehringer Ingelheim announced in a news release.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details